Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + busulfan
- Development stage
- Phase 4
- Lead developer
- Baxter
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
**cyclophosphamide + busulfan** is a chemotherapy conditioning regimen used primarily in preparation for hematopoietic stem cell transplantation (HSCT), particularly in patients with hematologic malignancies such as lymphoma and acute lymphoblastic leukemia. The combination is designed to ablate the patient's bone marrow prior to transplant. Busulfan is an alkylating agent that cross-links DNA, while cyclophosphamide is also an alkylating agent that causes DNA damage and immunosuppression. Together, they provide potent myeloablative effects necessary for successful engraftment of donor stem cells[1][3].
- Brand names
- Cytoxan
- Other names
- busulfan and cyclophosphamideBU/CY regimenBuCy regimen
02
Targets
DNA
Beyond the preview
Go deeper on cyclophosphamide + busulfan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + busulfan.